Business Description
Kazia Therapeutics Ltd
ISIN : US48669G1058
Share Class Description:
KZIA: ADRDescription
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.61 | |||||
| Equity-to-Asset | -0.46 | |||||
| Debt-to-Equity | -0.06 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -12.15 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -61.1 | |||||
| 3-Year EBITDA Growth Rate | -26.6 | |||||
| 3-Year EPS without NRI Growth Rate | -20.3 | |||||
| 3-Year FCF Growth Rate | 25.8 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 12.48 | |||||
| 9-Day RSI | 23.64 | |||||
| 14-Day RSI | 32.78 | |||||
| 3-1 Month Momentum % | 66.13 | |||||
| 6-1 Month Momentum % | 135.25 | |||||
| 12-1 Month Momentum % | 42.5 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.24 | |||||
| Quick Ratio | 0.24 | |||||
| Cash Ratio | 0.06 | |||||
| Days Sales Outstanding | 50.83 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -36.1 | |||||
| Shareholder Yield % | -21.17 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -1243.44 | |||||
| Net Margin % | -1162.95 | |||||
| FCF Margin % | -417.16 | |||||
| ROE % | -1077.87 | |||||
| ROA % | -108.04 | |||||
| ROIC % | -123.85 | |||||
| 3-Year ROIIC % | 310.22 | |||||
| ROCE % | -290.17 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 6.66 | |||||
| EV-to-EBIT | -0.77 | |||||
| EV-to-EBITDA | -0.83 | |||||
| EV-to-Forward-EBITDA | -1.19 | |||||
| EV-to-Revenue | 9.63 | |||||
| EV-to-Forward-Revenue | 2.03 | |||||
| EV-to-FCF | -2.31 | |||||
| Earnings Yield (Greenblatt) % | -129.87 | |||||
| FCF Yield % | -41.41 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:KZIA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Kazia Therapeutics Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1.533 | ||
| EPS (TTM) ($) | -6.766 | ||
| Beta | 1.38 | ||
| 3-Year Sharpe Ratio | -0.58 | ||
| 3-Year Sortino Ratio | -0.79 | ||
| Volatility % | 91.44 | ||
| 14-Day RSI | 32.78 | ||
| 14-Day ATR ($) | 0.594525 | ||
| 20-Day SMA ($) | 4.773135 | ||
| 12-1 Month Momentum % | 42.5 | ||
| 52-Week Range ($) | 1.866 - 15.8 | ||
| Shares Outstanding (Mil) | 4.35 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Kazia Therapeutics Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Kazia Therapeutics Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Kazia Therapeutics Ltd Frequently Asked Questions
What is Kazia Therapeutics Ltd(KZIA)'s stock price today?
The current price of KZIA is $3.55. The 52 week high of KZIA is $15.80 and 52 week low is $1.87.
When is next earnings date of Kazia Therapeutics Ltd(KZIA)?
The next earnings date of Kazia Therapeutics Ltd(KZIA) is 2025-02-28 Est..
Does Kazia Therapeutics Ltd(KZIA) pay dividends? If so, how much?
Kazia Therapeutics Ltd(KZIA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers